181 related articles for article (PubMed ID: 18794669)
1. Duloxetine treatment of social anxiety disorder with comorbid major depression.
Lin CC
J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
[No Abstract] [Full Text] [Related]
2. Duloxetine in the treatment of social anxiety disorder.
Crippa JA; Filho AS; Freitas MC; Zuardi AW
J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
[No Abstract] [Full Text] [Related]
3. Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression.
Chang JP; Wu CC
J Clin Psychopharmacol; 2012 Oct; 32(5):729. PubMed ID: 22926618
[No Abstract] [Full Text] [Related]
4. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
Lai CH
J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662
[No Abstract] [Full Text] [Related]
5. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
6. [Physical recovery is part of remission].
Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907
[No Abstract] [Full Text] [Related]
7. Duloxetine-induced cutaneous adverse reaction.
Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
[No Abstract] [Full Text] [Related]
8. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
9. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
10. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao MC; Liu CY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
[No Abstract] [Full Text] [Related]
11. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
12. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy.
Barkin RL; Barkin S
Am J Ther; 2005; 12(5):431-8. PubMed ID: 16148429
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
Rabasseda X
Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
15. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Ravindran LN; Eisfeld BS; Kennedy SH
J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
[No Abstract] [Full Text] [Related]
16. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
17. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
Davidson J; Allgulander C; Pollack MH; Hartford J; Erickson JS; Russell JM; Perahia D; Wohlreich MM; Carlson J; Raskin J
Hum Psychopharmacol; 2008 Aug; 23(6):519-26. PubMed ID: 18478624
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
Herrera-Guzmán I; Herrera-Abarca JE; Gudayol-Ferré E; Herrera-Guzmán D; Gómez-Carbajal L; Peña-Olvira M; Villuendas-González E; Joan GO
Psychiatry Res; 2010 May; 177(3):323-9. PubMed ID: 20385412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
